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A b s t r a c t  
A biodegradable nanoparticle has been used frequently as drug delivery carrier due to its better 
encapsulation capacity, sustained/ control release property and less toxicity. Gliclazide (GLZ) is a 
second generation of hypoglycemic sulfonylurea and acts selectively on pancreatic ß cell to control 
diabetes mellitus. The objective of this study was to produce controlled release nanoparticles of 
Gliclazide using poly (L-lactide-co-ē-caprolactone) (PLCL). The method was optimized using design 
of experiments by employing a 3-factor, 3-level Design Expert (version 8.0.7.1) Statistical Design 
Software and was subjected to various characterization studies including Field Emission Scanning 
Electron Microscopy (FE-SEM), X-ray diffraction (XRD), Encapsulation efficiency (%EE), Particle 
Size Distribution (PSD), etc. Formulated nanoparticles were also subjected to Fourier Transform 
Infrared Spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC) for studying interaction 
between drug and polymer and the effect of lyophilization (Freeze Drying) on developed 
nanoparticles.  The release profiles and encapsulation efficiencies are depended on the 
concentration of PLCL. These data demonstrated the efficacy of the biodegradable polymeric 
nanoparticles in controlling the gliclazide drug release profile as novel drug delivery system. 
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Introduction 
Diabetes mellitus is a chronic metabolic disorder characterized by 
high blood glucose concentrations (hyperglycemia) caused by 
insulin deficiency and it is often combined with insulin resistance[1]. 
Non-insulin-dependent diabetes mellitus (NIDDM) is a 
heterogeneous disorder, comprising milder forms of diabetes that 
occur predominately in adults. Most diabetic patients have 
NIDDM[2]. Gliclazide 1-(1-azabicyclo- [3,3,0]-oct-3-yl)-3-(p-
tolylsulfonyl urea)  is a potential second generation oral 
hypoglycemic agent widely used in the treatment of NIDDM. A full 
dose of GLZ is required before each meal; hence, therapy may 
become inconvenient[3].  
Nanoparticles (including nanospheres and nanocapsules of size 
10-200 nm) are in the solid state and are either amorphous or 
crystalline. They are able to absorb and/or encapsulate a drug, 
thus protecting it against chemical and enzymatic degradation. 
Nanocapsules are vesicular systems in which the drug is confined 
to a cavity surrounded by a unique polymer membrane, while 
nanospheres are matrix systems in which the drug is physically 
and uniformly dispersed. Nanoparticles as drug carriers can be 
formed from both biodegradable as well as non-biodegradable 
polymers. In recent years, biodegradable polymeric nanoparticles 
have attracted considerable attention as potential drug delivery 
devices in view of their applications in the controlled release of 
drugs, in targeting particular organs / tissues, as carriers of DNA in 
gene therapy, and in their ability to deliver proteins, peptides and 
genes through the peroral route [4]. For biodegradable polymers, 
researchers found that the degradation rate of these nanoparticles 
is nearly constant for a given set of experimental conditions, ideal 
for the controllable release of drugs. It is helpful to note that the 
degradation of these nanoparticles in dispersion is different from 
that of a bulk material [5].  Biodegradable polymers offer a novel 
approach for developing controlled/sustained release drug delivery 
systems that are simple and convenient to patient[6]. Controlled 
drug delivery take place when a polymer, whether natural or 
synthetic, is sensibly combined with a drug or other active agent in 
such a way that the active agent is released from the material in a 
predesigned manner [7].  Biodegradable polymers such as poly 
(glycolic acid), poly (lactic acid) (PLA) and their copolymers, poly 
(p-dioxanone), PLCL and copolymers of trimethylene carbonate 
and glycolide have been used in a number of clinical applications 
[8]. Solvent evaporation method to formulate micro-spheres of poly 
(lactic acid) (PLA), and its co-polymer poly (lactic-co-glycolic acid) 
(PLGA) has been studied extensively due to the biocompatibility of 
these polymers. The method of microencapsulation by solvent 
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evaporation is widely applied in pharmaceutical industries to obtain 
the controlled release of drug[9-12]. The formulation of 
biodegradable nanoparticles offers many advantages over 
conventional oral dosage forms. Drugs can be delivered in a 
sustained and continuous manner, encapsulated drugs are 
protected in the polymer network from gastric and enzymatic 
degradation and daily administration may not be required[13]. 
Controlled release systems (microparticles, nanoparticles, and 
liposome etc.) are prepared to obtain prolonged or controlled drug 
delivery, to improve bioavailability and to target drug to specific 
sites. These systems can also to protect drugs from degradation 
and reduce the toxicity or side effects [14-15]. Thus, the aim of the 
present study was to design a novel delivery system to maintain 
peak plasma levels of GLZ for the long-term management of 
diabetes mellitus. 
Materials and Methods 
Materials 
Gliclazide was obtained as gift a sample from Wockhardt Research 
Centre, Aurangabad (M.S.) India. Poly (L-lactide-co-ē-caprolactone) 
(PLCL) polymer, Dichloromethane (DCM), hydrophilic surfactant 
polyvinyl alcohol (PVA) and n-Hexane was obtained from Merk Pvt. 
Ltd. All other chemicals and materials were of analytical grade and 
were used as procured. 
Preparation of Nanoparticles 
Preparation Poly (L-lactide-co-ē-caprolactone) (PLCL) 
loaded Gliclazide Nanoparticles by solvent evaporation 
- high pressure homogenization method (HPH) 
Polymer and drug was dissolved in Dichloromethane (DCM), mixed 
properly till to obtained homogeneous solution, this organic solution 
was then added into polyvinyl alcohol (dissolved in water) with 
constant stirring at 1200 rpm at room temperature, oil -in-water 
(o/w) type emulsion was formed. The formed emulsion were stirred 
for 4 hr using lab mechanical stirrer (Remi) at 500 rpm and kept 
overnight for removal of residual organic (DCM) solvent[16]. 
Formulated microparticles were collected and then subjected to 
high pressure homogenization. Homogenization was carried out at 
400 bars for three cycles. The processed emulsion was evaporated 
overnight to remove the residual DCM. The final emulsion was 
centrifuged at about 10000 rpm for 15 min, then kept for 
Lyophilization (freeze-drying) for 48 hrs [17]. The obtained free 
flowing nanoparticles were stored in desiccator for further analysis. 
Physiochemical Characterization of NPs 
Particle size and zeta potential 
The average particle size and zeta potential of the Poly (L-lactide-
co-ē-caprolactone) (PLCL) loaded Gliclazide nanoparticles were 
determined by Particle Size Analyzer (Zetasizer Ver System; Serial 
Number: MAL 1051945; Malvern Instruments Ltd, Malvern, UK) at 
temperature -25 0C, Count Rate (kcps): 557.2, duration used: 40s, 
cell Description: Disposable sizing cuvette at Attenuator:11. The 
result of average particle size is shown in Figure 1. 
 
 
Fig 1: Average particle size 
 
 
 
 
 
Naik et al. International Journal of Drug Delivery 5 (3) 300-308 [2013] 
 
PAGE | 302 |
 
 
Encapsulation Efficiency  
Table 1: Encapsulation Efficiency of Gliclazide nanoparticles embedded in the PLCL matrix 
 
Std. Run Drug 
(mg) 
Factor 1 Factor 2 Response:
Encapsulation 
efficiency (%) 
Drug loading 
(%) A:Polymer B:Surfactant
(mg) (mg)
1 3 100 100 150 70.30 35.15 
2 2 100 200 150 73.54 36.70 
3 1 100 300 150 81.37 40.68 
4 8 100 100 300 68.13 22.68 
5 7 100 200 300 71.84 23.91 
6 5 100 300 300 78.86 26.25 
7 6 100 100 450 60.00 15.00 
8 4 100 200 450 66.28 16.57 
9 9 100 300 450 68.42 17.10 
 
Figure 2: 3-D graph (Map) of Encapsulation Efficiency of fresh O/W emulsions processed by HPH between 100 and 400 MPa (single-stage, 
single-pass homogenization; Tin =24 0C) for Poly (L-lactide-co-ē-caprolactone) (PLCL) loaded Gliclazide Nanoparticles 
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Differential Scanning calorimetry 
Thermo gravimetric analysis was carried out using a DSC, Model-
821, Make- Mettler Toledo from 25 to 300 ĈC at a heating rate of 2 
ĈC/min under a nitrogen atmosphere (Fig. 5). 
 
 
Figure 5: A] DSC of pure Gliclazide, B] DSC of pure PLCL polymer 
and C] DSC of Gliclazide nanoparticles embedded in the PLCL 
matrix. 
Interpretation of FTIR spectra 
The principle peaks of gliclazide were obtained at wave numbers 
3271.38, 3115.14, 1708.99 1595.18, 1437.02, 1350.22. (3271.38 
cm-1 ) for N-H stretching,  (3115.14 cm-1 ) for  =C-H stretching,  
(1708.99 cm-1 ) for O=C stretching, (1595.18 cm-1  ) for aromatic 
nucleus, (1437.02 cm-1  ) for C-H deformation, and (1350.22  cm-1 ) 
for  SO2-NH stretching. 
X-ray diffraction analysis (XRD) 
The state of gliclazide, its physical mixtures and solid dispersions 
were evaluated with X-ray powder diffraction. Diffraction patterns 
were obtained using D8 ADVANCE diffractometer with Vario1 
Johansson focusing monochromator features high-flux K-alpha-1 
radiation with DAVINCI design (Bruker AXS) with a radius of 240 
mm. The Cu Kđ radiation (Kđ 1.54060 Å) was Ni filtered. A system 
of diverging and receiving slits of 1Ĉ and 0.1 mm, respectively, was 
used. The pattern was collected with 40 kV of tube voltage and 40 
mA of tube current and scanned over the 2θ range of 5ă60Ĉ (Fig. 
7).  
 
 
 
       Figure 6: FT-IR spectra of A] pure Gliclazide, B] pure PLCL polymer and  C] Gliclazide nanoparticles embedded in the PLCL matrix. 
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 Figure  7: XRD pattern for pure Gliclazide, pure PLCL polymer, and Gliclazide Loaded  PLCL Nanoparticles  
 
Encapsulation Efficiency  
The amount of gliclazide entrapped within NP was determined 
using following equation: 
% E.E. = [wt. of drug determined (mg) / wt. of dug added (mg)] x 
100         (1) 
For estimation of drug loading, the freeze-dried nanoparticles 
containing around 5 mg of gliclazide was dissolved in 5 ml of 
methanol and 5 ml of pH 7.4 Phosphate buffer solution, after 
complete evaporation of methanol, the drug content was analyzed 
using a UV-Spectrophotometer (U-2900; Hitachi, UV/VIS  
spectrophotometer 200V) at 225.5 nm. 
Calibration curve of Gliclazide  
The absorbance was measured at 225.5 nm using double beam 
UV/Visible spectrophotometer, (Figure. 8). 
 
 
Figure 8:Calibration curve of Gliclazide 
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In vitro drug release studies- 
In vitro dissolution studies of the nanoparticles were carried out 
using USP type II (TDT 08T, Electro-lab, Mumbai, Maharashtra, 
India) dissolution test apparatus. The dissolution test for all the 
formulations was carried out in standard phosphate buffer saline 
(pH 7.4) maintained at   37 μ 0.50C at the paddle rotation speed of 
100 rpm. The conditions for in vitro were maintained to study the 
release behavior of a hydrophobic drug. Solubility of Gliclazide 
increases 3ă6 times with phosphate buffer (pH 7.4) as solvent. 
Hence, the drug release study was carried out using phosphate 
buffer pH 7.4. Samples of nanoparticles containing Gliclazide were 
suspended in 900 ml of standard phosphate buffer saline, pH 7.4, 
and stirred at 100 rpm. Withdrawing 5 ml of samples at preselected 
time intervals up to 24 hours monitored progress of the dissolution. 
Same volume of dissolution medium was replenished after each 
sampling. The sample solutions were filtered and diluted up to 10 
ml and the absorbance was measured at 225.5 nm using Double 
Beam UV/VIS Spectrophotometer. 
 
 
 
Figure 9: % cumulative drug release from controlled release nanoparticles 
 
Result- 
In our study, our attempt was to encapsulate gliclazide with the 
PLCL biodegradable polymer for sufficiently high entrapment 
efficiency by O/W single emulsion solvent evaporation method and 
then to obtained a nanosize under High Pressure Homogenizer. 
The importance of enhanced drug entrapment efficiency in 
nanoparticles has been emphasized earlier, since a nanoparticles 
recovery is required for reducing manufacturing costs and its size 
and morphology important for quality control and biodistribution, it 
was necessary to study the influence of processing parameters on 
nanoparticles preparation. Solvent evaporation method was used 
to prepare PLCL loaded nanoparticles. Different Gliclazide: PLCL 
ratios were tried. The effect of drug:polymer ratio on encapsulation 
efficiency is shown in table no.1,  Initially various solvents like 
acetone, methanol and DCM were tried for preparation of 
nanoparticles. However, maximum solubility and encapsulation 
efficiency of gliclazide found only when DCM is used as an organic 
phase. Hence DCM used as an organic phase. All the optimized 
batches were further employed for particle size reduction using 
high pressure homogenizer (Panda Plus-200) which reduces the 
particle size up to 100 nm which is shown in the figure no. 4. PVA 
with concentration up to 0.3% shows excellent encapsulation 
efficiency with particle size reduction for Poly (L-lactide-co-ē-
caprolactone) (PLCL) loaded Gliclazide biodegradable nanoparticle 
formulation.  
The % cumulative release of Gliclazide from PLCL NPs was almost 
complete after 2 h, due to a single and rapid desorption process 
from the PLCL surface. The release of GLZ from PLCL NPs, it was 
observed a biphasic process with an early rapid release which took 
place within 2-5 h (up to ‘75% and 80%, respectively), the 
remaining drug being slowly liberated during the next 26 h as 
controlled release property of the nanoparticles (Fig. 9).  GLZ 
release during the faster release phase may result polymer 
degradation which has been reported to be a very high solubility in 
the pH-7.4, suggests that the major fraction of GLZ was entrapped 
into the PLCL polymeric network rather than adsorbed onto the NP 
surface, which determined more complex drug diffusion through 
the polymeric shell. 
Conclusions 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30
%
 D
ru
g 
R
el
ea
se
Time (Hrs)
Dissolution profile in pH 7.4 Phospahte Buffer
Naik et al. International Journal of Drug Delivery 5 (3) 300-308 [2013] 
 
PAGE | 307 |
 
 
From the results it can be concluded that the Gliclazide has 
successfully encapsulated in PLCL polymer employing O/W 
solvent evaporation and HPH method. Nanoparticles was 
successfully developed using response surface methodology by 32 
factorial designs. PLCL polymeric matrix has yielded higher 
encapsulation efficiency and drug loading with potential carrier for 
efficient delivery of Gliclazide. In vitro drug release from 
microspheres followed a controlled drug release pattern. 
Nanoparticles prepared by such method may represent a 
promising approach for efficient delivery of Gliclazide.  
Future perspective  
In this study we have formulated successfully Gliclazide 
encapsulated PLCL biodegradable nanoparticles, however, in this 
novel drug delivery system including the field of nanomedicine is 
very beneficial for the patient who is and will be suffer from 
Diabetes a life threatening diseases. In future this kind of work 
should be carried out for further formulation or drug delivery 
systems to avoid the excess use of filler which is traditionally in the 
use of formulation for conventional dosage forms and we have to 
move towards nanotechnology for better patient compliance and to 
save them from this type of life threatening diseases.  
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